Jaguar's Mytesi Could Be Used to Treat GI Side Effects of GLP-1 Weight Loss Drugs

Seeking AlphaJan 29 09:55 ET

Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application With USPTO

Jaguar HealthJan 29 00:00 ET

Jaguar Health Announces First Patient Dosed In UAE POC Trial For Crofelemer In Pediatric MVID; Potential For Early Access In Europe By H1 2025; Drug Holds Orphan Designation For MVID And SBS-IF By FDA And EMA

BenzingaJan 22 09:03 ET

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar HealthJan 10 00:00 ET

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

Jaguar HealthJan 8 00:00 ET

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Jaguar HealthJan 7 00:00 ET